ARTICLE | Clinical News
Lexaptepid pegol: Phase IIa data
July 20, 2015 7:00 AM UTC
Data from 9 patients in the single-blind, crossover Part 1 of a 2-part, double-blind, placebo-controlled, U.K. Phase IIa trial showed that NOX-H94 was generally well tolerated and all adverse events o...